ESMO 2019: BeiGene presents data on tislelizumab and pamiparib - 0 views
-
ramchintamaneni on 17 Oct 19Biopharmaceutical company BeiGene has presented data on its two investigational drug candidates, anti-PD-1 antibody tislelizumab and PARP inhibitor pamiparib.